The expansion gives the company diversified capacity running cell production lines featuring Sartorius-brand 2000-L disposable bioreactors and now GE-brand 2000-L single-use bioreactors.
MabPlex International, a contract development and manufacturing organization has started operations of two cell culture production lines of GE-brand 2000-L single-use bioreactors, the company announced on Feb. 25.
In addition, the company will further expand by adding two more production lines by the end of March 2020, which will feature Thermo-Fisher Scientific-brand 2000-L disposable bioreactors for clinical production. The company already runs Sartorius brand 2000-L disposable bioreactors.
"MabPlex offers one of the few globally integrated service platforms with high production capacity, something that is unique in our industry," said Yongjian Wu, PhD, chief operating officer, MabPlex USA, in a company press release.
The company has previously introduced a variety of international mainstream brand equipment for independent production lines to carry out multiple contract manufacturing processes designed to meet the varying needs of global customers. The company’s approach significantly reduces customer cost and shortens the drug-to-market cycle, according to the press release.
Source: MabPlex USA
Thermo Fisher Opens Advanced Therapies Collaboration Center in California
April 18th 2025The 6000-square-foot facility will provide cell therapy developers the support they need to transition to CGMP manufacturing, and an expanded footprint of the new center is expected to open in Philadelphia later in 2025.